Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Language
Publication year range
1.
J Gastrointest Surg ; 27(11): 2661, 2023 11.
Article in English | MEDLINE | ID: mdl-37464141

ABSTRACT

OBJECTIVE: We demonstrate a surgical technique involving construction of a hepaticojejunostomy (HJ) anastomosis that ensures even spacing between the sutures regardless of the size of the common bile duct. This is demonstrated via a series of illustrations followed by live demonstration of a HJ anastomosis created during a Whipple procedure. VIDEO DESCRIPTION: Overall, this technique results in the creation of a tension-free hepaticojejunostomy anastomosis, that typically does not require stenting, is highly reliable and replicable regardless of the size of the common bile duct. It is also easily reproducible and easy to teach trainees.


Subject(s)
Biliary Tract Surgical Procedures , Liver , Humans , Anastomosis, Surgical/methods , Liver/surgery , Gallbladder/surgery , Biliary Tract Surgical Procedures/methods , Sutures , Bile Ducts/surgery
2.
J Thorac Cardiovasc Surg ; 166(2): 383-393.e13, 2023 08.
Article in English | MEDLINE | ID: mdl-36967372

ABSTRACT

OBJECTIVE: The study objective was to determine effects of donor smoking and substance use on primary graft dysfunction, allograft function, and survival after lung transplant. METHODS: From January 2007 to February 2020, 1366 lung transplants from 1291 donors were performed in 1352 recipients at Cleveland Clinic. Donor smoking and substance use history were extracted from the Uniform Donor Risk Assessment Interview and medical records. End points were post-transplant primary graft dysfunction, longitudinal forced expiratory volume in 1 second (% of predicted), and survival. RESULTS: Among lung transplant recipients, 670 (49%) received an organ from a donor smoker, 163 (25%) received an organ from a donor with a 20 pack-year or more history (median pack-years 8), and 702 received an organ from a donor with substance use (51%). There was no association of donor smoking, pack-years, or substance use with primary graft dysfunction (P > .2). Post-transplant forced expiratory volume in 1 second was 74% at 1 year in donor nonsmoker recipients and 70% in donor smoker recipients (P = .0002), confined to double-lung transplant, where forced expiratory volume in 1 second was 77% in donor nonsmoker recipients and 73% in donor smoker recipients. Donor substance use was not associated with allograft function. Donor smoking was associated with 54% non-risk-adjusted 5-year survival versus 59% (P = .09) and greater pack-years with slightly worse risk-adjusted long-term survival (P = .01). Donor substance use was not associated with any outcome (P ≥ 8). CONCLUSIONS: Among well-selected organs, lungs from smokers were associated with non-clinically important worse allograft outcomes without an inflection point for donor smoking pack-years. Substance use was not associated with worse allograft function. Given the paucity of organs, donor smoking or substance use alone should not preclude assessment for lung donation or transplant.


Subject(s)
Lung Transplantation , Primary Graft Dysfunction , Humans , Retrospective Studies , Smoking/adverse effects , Tissue Donors , Lung Transplantation/adverse effects , Graft Survival
3.
J Thorac Cardiovasc Surg ; 164(3): 711-719.e4, 2022 09.
Article in English | MEDLINE | ID: mdl-35151488

ABSTRACT

OBJECTIVES: Gastroparesis is a debilitating and difficult to manage problem that has been reported in 20% to 90% of lung and heart-lung transplant recipients. The primary objective was to evaluate the safety and clinical effectiveness of per-oral endoscopic pyloromyotomy in relieving gastroparesis after lung transplant. Secondary objectives evaluated the effect of per-oral endoscopic pyloromyotomy on gastroesophageal reflux and allograft function. METHODS: Fifty-two lung transplant recipients underwent per-oral endoscopic pyloromyotomy for refractory gastroparesis. Gastroparesis was assessed by a pre-per-oral endoscopic pyloromyotomy and post-per-oral endoscopic pyloromyotomy radionuclide gastric emptying test and Gastroparesis Cardinal Symptom Index. Secondary outcomes included 90-day complications, gastroesophageal reflux as measured by pH testing, and longitudinal spirometry measurements. RESULTS: Median time from lung transplant to per-oral endoscopic pyloromyotomy was 10.5 months. Twenty-eight patients had prior pyloric botulinum injection with either no improvement or relapse of symptoms. Post-per-oral endoscopic pyloromyotomy gastric emptying tests were available for 32 patients and showed a decrease in median gastric retention at 4 hours from 63.5% pre-per-oral endoscopic pyloromyotomy to 5.5% post-per-oral endoscopic pyloromyotomy (P < .0001). Complete normalization of gastric emptying time was noted in 19 patients. Gastroparesis Cardinal Symptom Index score significantly improved after per-oral endoscopic pyloromyotomy (median, 23-3.5; P < .0001). Post-per-oral endoscopic pyloromyotomy pH testing showed improved or stable DeMeester score in all patients except 1. Graft function (forced expiratory volume in 1 second) remained stable 1 year after per-oral endoscopic pyloromyotomy. CONCLUSIONS: The improvements in symptom score and radionuclide imaging observed in this uncontrolled study suggest that per-oral endoscopic pyloromyotomy is an effective strategy in the lung transplant population and can be performed with minimal morbidity.


Subject(s)
Gastroesophageal Reflux , Gastroparesis , Lung Transplantation , Pyloromyotomy , Gastroesophageal Reflux/complications , Gastroparesis/diagnostic imaging , Gastroparesis/etiology , Gastroparesis/surgery , Humans , Lung Transplantation/adverse effects , Neoplasm Recurrence, Local , Pyloromyotomy/adverse effects , Treatment Outcome
6.
J Heart Lung Transplant ; 40(7): 623-630, 2021 07.
Article in English | MEDLINE | ID: mdl-33994081

ABSTRACT

BACKGROUND: Pleural complications after lung transplant may restrict allograft expansion, requiring decortication. However, its extent, indications, risk factors, and effect on allograft function and survival are unclear. METHODS: From January 2006 to January 2017, 1,039 patients underwent primary lung transplant and 468 had pleural complications, 77 (16%) of whom underwent 84 surgical decortications for pleural space management. Multivariable time-related analysis was performed to identify risk factors for decortication. Mixed-effect longitudinal modeling was used to assess allograft function before and after decortication. RESULTS: Cumulative number of decortications per 100 transplants was 1.8, 7.8, and 8.8 at 1 month, 1 year, and 3 years after transplant, respectively. Indications for the 84 decortications were complex effusion in 47 (56%), fibrothorax in 17 (20%), empyema in 11 (13%), and hemothorax in 9 (11%). Thoracoscopic operations were performed in 52 (62%) and full lung re-expansion was achieved in 76 (90%). Complications occurred after 30 (36%) decortications, with 15 pulmonary complications (18%), including 2 patients requiring extracorporeal support due to worsening function. Ten reinterventions occurred via thoracentesis (2), tube thoracostomy (1), and reoperation (7). In-hospital and 30-day mortality was 5.2% (n = 4/77). Forced expiratory volume in 1 second increased from 50% to 60% within the first year after decortication, followed by a slow decline to 55% at 5 years. Postdecortication survival was 87%, 68%, and 48% at 1, 3, and 5 years, respectively. CONCLUSIONS: Despite high risk of reoperative surgery, decortication after lung transplant allows salvage of pleural space and graft function with a reasonable morbidity profile.


Subject(s)
Lung Transplantation/adverse effects , Pleura/surgery , Pleural Diseases/epidemiology , Postoperative Complications/epidemiology , Thoracotomy/methods , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Ohio/epidemiology , Pleural Diseases/surgery , Postoperative Complications/surgery , Reoperation , Retrospective Studies , Risk Factors , Time Factors
7.
Surg Oncol Clin N Am ; 29(4): 581-601, 2020 10.
Article in English | MEDLINE | ID: mdl-32883460

ABSTRACT

Thymomas are relatively indolent tumors that present with locally advanced disease in 30% of the patients. Thymic carcinoma is a more aggressive histology with shorter disease-free and overall survival. Early-stage tumors are managed best with complete resection. Multimodal therapy is the standard of care for locally advanced tumors and neoadjuvant therapy may help improve respectability. Stage and complete resection are the strongest prognostic factors for long-term survival. Based on early experience, targeted and immunotherapies have shown limited promise in advanced disease.


Subject(s)
Neoplasm Staging/standards , Thymus Neoplasms/pathology , Thymus Neoplasms/therapy , Combined Modality Therapy , Disease Management , Humans , Thymus Neoplasms/classification
8.
J Surg Oncol ; 119(1): 64-70, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30481370

ABSTRACT

BACKGROUND: The three-delays model describes delays in seeking, reaching, and receiving care for vulnerable populations needing treatment. The dominant delay for patients with gastric adenocarcinoma (GAC) is unknown. We aimed to define patients with GAC who reached and received care at our regional safety-net hospital (Grady Memorial Hospital [GMH]) and our neighboring quaternary referral hospital (Emory University Hospital [EUH]). METHODS: Clinicopathologic data from National Cancer Database (NCDB) participating academic centers were compared with GMH from 2004 to 2014. Outcomes of patients undergoing surgery at GMH were compared to those at EUH. RESULTS: At presentation, compared to NCDB centers (n = 69 662), GMH patients (n = 154) were more often black (85.1 vs 17.2%; P < 0.001), uninsured (30.5 vs 4.7%; P < 0.001), have stage IV disease (43.5 vs 30.1%; P = 0.017), and received no treatment (40.3 vs 18.4%; P < 0.001). When only comparing patients who underwent curative-intent resection at GMH (n = 23) to EUH (n = 137), median overall survival was similar between both groups (GMH: median not reached; EUH: 59.8 mos; P = 0.785). CONCLUSION: Although vulnerable patients with GAC within a safety-net hospital present with later stages of the disease, those who received surgery have acceptable outcomes. Thus, efforts should be made to overcome barriers in seeking care.


Subject(s)
Adenocarcinoma/surgery , Health Services Accessibility/statistics & numerical data , Hospitals/statistics & numerical data , Practice Patterns, Physicians'/standards , Referral and Consultation , Safety-net Providers/standards , Stomach Neoplasms/surgery , Adenocarcinoma/epidemiology , Adenocarcinoma/pathology , Female , Follow-Up Studies , Healthcare Disparities , Humans , Male , Middle Aged , Prognosis , Quality of Health Care , Retrospective Studies , Stomach Neoplasms/epidemiology , Stomach Neoplasms/pathology , Survival Rate , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL